全链条支持医药和医疗器械发展 深圳推出32条政策措施 覆盖近年涌现的新技术新赛道新业态

Core Viewpoint - Shenzhen's new measures aim to significantly boost the pharmaceutical and medical device industries through comprehensive support across the entire development chain [1][3]. Group 1: Policy Measures - The new policy includes 32 specific measures focusing on nine key areas: R&D innovation, AI application, clinical trials, registration and approval, production, promotion, international expansion, talent and financial empowerment, and investment promotion [1][2]. - The measures align with national and provincial requirements for supporting innovative pharmaceuticals and medical devices, covering emerging technologies and new business models such as AI-enhanced pharmaceuticals and medical devices, biomanufacturing, and gene therapy [1][2]. Group 2: AI and Biomanufacturing - The policy promotes the application of AI in biomanufacturing and pharmaceutical R&D, supporting the establishment of major public service platforms and industrial projects [2]. - It encourages collaboration between innovative companies and AI service platforms, providing financial support of up to 200 million yuan per year for contract R&D expenses [2]. Group 3: Financial Incentives - The policy offers substantial financial rewards for innovative drug development, with up to 3 million yuan available for each phase of clinical trials for first-class innovative drugs [3]. - Shenzhen's pharmaceutical industry is projected to reach nearly 55 billion yuan in output value by 2024, marking a historical high [3]. Group 4: Industry Goals - By 2025, Shenzhen aims to become a globally recognized center for innovative drug R&D, with the biopharmaceutical industry's added value reaching 40 billion yuan and total revenue hitting 100 billion yuan [3].